News

Women with a rare and potentially aggressive form of ovarian cancer will benefit from a grant to continue ground-breaking research into new detection and treatment methods.…  Read more

Dr Robin Hobbs has joined Hudson Institute as Group Head, Germline Stem Cell Biology. We welcome him and his team, including postdoctoral scientists Dr Ai-Leen Chan and Dr Julien Legrand, and PhD student Mai La.…  Read more

More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nation’s scientists need to be part of the global effort to address this pandemic.…  Read more

There is something unusual about the initial—or innate—immune response to COVID-19 compared to usual influenza patterns. …  Read more

Severe COVID-19 infection presents as excessive lung inflammation, involving the build-up of cells and fluid in the lungs. This phenomenon, known as ARDS, restricts breathing and causes damage to the lungs. Severely affected patients will need ventilator assistance in intensive care.…  Read more

Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.…  Read more

Disruptions to male babies’ development early during pregnancy could have a profound effect on a man’s future reproductive health, according to new research.…  Read more

Ben Amberg and Mikee Inocencio are, in their own words, “two bros who met while doing PhDs”.
When COVID-19 hit, the friends found themselves, like many of us, in a whole new world in lockdown without their daily banter.…  Read more

There’s been a reported surge in women seeking home births since the outbreak of coronavirus in Australia.
Research led by Hudson Institute has shown home birth is safe for women with low-risk pregnancies.…  Read more

Biotech company Noxopharm is seeking approval from the US FDA for a clinical trial in COVID-19 patients of an end-stage prostate cancer drug, following a discovery by Hudson Institute researchers that it could act as an anti-inflammatory.…  Read more